<DOC>
	<DOCNO>NCT02120157</DOCNO>
	<brief_summary>We propose multi-institutional phase II haplo-identical T cell replete BMT study child high-risk leukemia . The myeloablative conditioning regimen prescribe TBI-based lymphoid leukemias busulfan-based myeloid leukemia . Our goal establish easily exportable , inexpensive platform haplotransplantation safety profile equivalent match relate unrelated BMTs . The primary objective estimate incidence 6-month non-relapse mortality , hypothesize NRM &lt; 18 % .</brief_summary>
	<brief_title>Phase II Trial Myeloablative Conditioning &amp; Transplantation Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide Peds Pts w/ Hematologic Malignancies</brief_title>
	<detailed_description>This phase II prospective study design evaluate incidence 6 month non- relapse mortality , safety , feasibility haploidentical bone marrow transplantation ( BMT ) myeloablative condition post-transplant Cy . Conditioning regimen include total body irradiation-based prep lymphoid leukemia chemotherapy base prep myeloid leukemia . To estimate incidence non-relapse mortality 180 day follow myeloablative haploidentical BMT child young adult high risk hematologic malignancy .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient age 0.525years Patients must firstdegree related donor halfsibling minimum HLA haploidentical . The donor recipient must identical least one allele follow genetic locus : HLAA , HLAB , HLACw , HLADRB1 , HLADQB1 . A minimum match 5/10 therefore require , consider sufficient evidence donor recipient share one HLA haplotype . An unrelated donor search require patient eligible protocol , donor search donor mobilization may abandon clinical situation dictate urgent transplant . Clinical urgency define 68 week referral transplant lowlikelihood find match , unrelated donor . Patients eligible HLAmatched RELATED enrol trial . Patients must least one follow highrisk condition list ( criterion mean complement exist criterion within COG protocol ) : Acute lymphocytic leukemia ( ALL ) CR1* define least one following : hypodiploidy , induction failure , MRD consolidation Acute myeloid leukemia ( AML ) CR1 high risk feature define : High allelic ratio FLT3/ITD+ , Monosomy 7 , Del ( 5q ) , Standard risk cytogenetics positive minimal residual disease end Induction I chemotherapy ( patient treat accord COG AAML1031 MRD study send Seattle perform local institution flow assay sensitive enough detect &gt; 0.1 % blast ) Acute Leukemias 2nd subsequent CR ( CR &gt; 2 ) Mixed phenotype/Undifferentiated Leukemias 1st subsequent CR* Secondary therapy relate leukemias CR &gt; 1 NK cell lymphoblastic leukemia CR &gt; 1 Myelodysplastic syndrome ( MDS ) JMML ( patient eligible eligible COG1221 ) Prior transplant eligible &lt; 18yo , &gt; 6 month elapse since BMT , patient immunosuppression &gt; 3 month GVHD No known active CNS involvement extramedullary involvement malignancy . Such disease treat remission permit . Acute Leukemia Remission define morphology &lt; 5 % blast morphological characteristic acute leukemia ( e.g. , Auer Rods ) bone marrow &gt; 20 % cellularity . Patients exclude basis sex , racial ethnic background . Poor cardiac function : leave ventricular ejection fraction &lt; 45 % determined MUGA ECHO . For pediatric patient LVEF &lt; 45 % shorten fraction normal limit age . Symptomatic pulmonary disease . Poor pulmonary function : FEV1 , FVC , DLCO &lt; 50 % predict ( correct hemoglobin ) patient receive thoracic mantle irradiation . For patient receive thoracic mantle irradiation , FEV1 FVC &lt; 70 % predict DLCO &lt; 50 predict . For child unable perform PFTs developmental stage pulse oximetry &lt; 92 % RA . Poor liver function : bilirubin &gt; 2 mg/dl ( due hemolysis , Gilbert 's primary malignancy ) . ALT AST &gt; 3 x laboratory upper normal limit . Poor renal function : Creatinine &gt; 2.0mg/dl creatinine clearance ( calculated creatinine clearance permit ) &lt; 60 mL/min base Traditional CockcroftGault formula : 140 age ( yr ) x Smaller Actual Weight v . Ideal Body Weight ( kg ) / 72 x Serum creatinine ( mg/dl ) Multiply another factor 0.85 female Intended age 18110 , serum creatinine 0.67 mg/dl For patient &lt; 18 year : CrCl estimate Schwartz formula . A measured CrCl GFR may substitute determine subject 's CrCl . Schwartz equation : CrCl ( ml/min/1.73m2 ) = [ length ( cm ) x k ] /serum creatinine K = 0.45 infant 1 52 week old k = 0.55 child 1 13 year old k = 0.55 adolescent female 1318 year old k = 0.7 adolescent male 1318 year old HIVpositive Positive leukocytotoxic crossmatch Specifically , complement dependent cytotoxicity flow cytometric crossmatch assay must negative , mean fluorescence intensity ( MFI ) antidonor HLA antibody solid phase immunoassay &lt; 3000 . Consult PI clinical significance antidonor antibody . Women childbearing potential currently pregnant ( HCG+ ) practice adequate contraception breastfeed Uncontrolled viral , bacterial , fungal infection ( currently take medication progression clinical symptom ) Patients symptoms consistent RSV , influenza A , B , parainfluenza time enrollment assayed virus positive eligible trial longer symptomatic ( patient may continue assay positivity period time post resolution symptom secondary nature assay</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Juvenile myelomonocytic leukemia</keyword>
	<keyword>Treatment relate leukemia</keyword>
	<keyword>Biphenotypic leukemia</keyword>
</DOC>